STOCK TITAN

[6-K] Smith & Nephew plc Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

NIKE, Inc. (NKE) has filed a Form 144 indicating that an insider intends to sell 1,644 Class B shares, valued at roughly $123,152, through Fidelity Brokerage on or after 05 Aug 2025. The shares were acquired only four days earlier (01 Aug 2025) via restricted-stock vesting and represent just 0.00014 % of the company’s 1.188 billion shares outstanding. No other insider sales were reported for the past three months. By signing the notice, the filer affirms awareness of no undisclosed material information regarding NIKE’s operations.

NIKE, Inc. (NKE) ha presentato un Modulo 144 che indica l’intenzione di un insider di vendere 1.644 azioni di Classe B, valutate circa 123.152 $, tramite Fidelity Brokerage a partire dal 05 agosto 2025. Le azioni sono state acquisite solo quattro giorni prima (01 agosto 2025) tramite vesting di azioni vincolate e rappresentano appena lo 0,00014% delle 1,188 miliardi di azioni in circolazione della società. Negli ultimi tre mesi non sono state segnalate altre vendite da parte di insider. Firmando l’avviso, il dichiarante conferma di non essere a conoscenza di informazioni materiali non divulgate riguardanti le operazioni di NIKE.

NIKE, Inc. (NKE) ha presentado un Formulario 144 indicando que un insider tiene la intención de vender 1.644 acciones Clase B, valoradas en aproximadamente 123.152 $, a través de Fidelity Brokerage a partir del 05 de agosto de 2025. Las acciones fueron adquiridas apenas cuatro días antes (01 de agosto de 2025) mediante vesting de acciones restringidas y representan solo el 0,00014% de las 1.188 mil millones de acciones en circulación de la empresa. No se reportaron otras ventas de insiders en los últimos tres meses. Al firmar el aviso, el declarante afirma no tener conocimiento de información material no divulgada sobre las operaciones de NIKE.

NIKE, Inc. (NKE)는 내부자가 2025년 8월 5일 이후 Fidelity Brokerage를 통해 약 123,152달러 상당의 1,644 클래스 B 주식을 매도할 의사를 밝힌 Form 144를 제출했습니다. 해당 주식은 제한 주식 권리 행사를 통해 단 4일 전인 2025년 8월 1일에 취득되었으며, 회사의 총 발행 주식 11억 8,800만 주0.00014%에 해당합니다. 지난 3개월간 다른 내부자 매도는 보고되지 않았습니다. 신고서에 서명함으로써 신고자는 NIKE의 운영과 관련된 미공개 중요 정보가 없음을 확인했습니다.

NIKE, Inc. (NKE) a déposé un Formulaire 144 indiquant qu’un initié prévoit de vendre 1 644 actions de classe B, d’une valeur d’environ 123 152 $, via Fidelity Brokerage à compter du 5 août 2025. Ces actions ont été acquises seulement quatre jours plus tôt (1er août 2025) par le biais d’un vesting d’actions restreintes et représentent seulement 0,00014 % des 1,188 milliard d’actions en circulation de la société. Aucune autre vente d’initiés n’a été signalée au cours des trois derniers mois. En signant cet avis, le déclarant affirme ne pas avoir connaissance d’informations matérielles non divulguées concernant les opérations de NIKE.

NIKE, Inc. (NKE) hat ein Formular 144 eingereicht, das darauf hinweist, dass ein Insider beabsichtigt, 1.644 Class-B-Aktien im Wert von etwa 123.152 $ über Fidelity Brokerage am oder nach dem 05. August 2025 zu verkaufen. Die Aktien wurden erst vier Tage zuvor (01. August 2025) durch restricted-stock vesting erworben und stellen lediglich 0,00014 % der insgesamt 1,188 Milliarden ausstehenden Aktien des Unternehmens dar. In den letzten drei Monaten wurden keine weiteren Insiderverkäufe gemeldet. Mit der Unterzeichnung der Mitteilung bestätigt der Einreicher, dass ihm keine nicht offengelegten wesentlichen Informationen über die Geschäftstätigkeiten von NIKE bekannt sind.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: 1,644-share ($123k) sale is de-minimis; neutral market impact.

The proposed disposition equals a microscopic fraction of NIKE’s float and does not change insider ownership trends meaningfully. Rule 144 filings of this size rarely influence liquidity or sentiment, especially against NIKE’s ~$160 bn market cap. No pattern of continuous selling is disclosed, and the shares stem from recent compensation, a routine source of insider supply. I view the event as administratively routine with no valuation implications.

TL;DR: Routine vest-and-sell; governance risk negligible.

The filing complies with Rule 144 requirements, includes broker details, and confirms no material non-public information. Absence of a 10b5-1 plan date suggests discretional timing, yet the token size reduces any appearance-of-impropriety concerns. Governance observers will likely deem the transaction immaterial and consistent with standard executive liquidity practices.

NIKE, Inc. (NKE) ha presentato un Modulo 144 che indica l’intenzione di un insider di vendere 1.644 azioni di Classe B, valutate circa 123.152 $, tramite Fidelity Brokerage a partire dal 05 agosto 2025. Le azioni sono state acquisite solo quattro giorni prima (01 agosto 2025) tramite vesting di azioni vincolate e rappresentano appena lo 0,00014% delle 1,188 miliardi di azioni in circolazione della società. Negli ultimi tre mesi non sono state segnalate altre vendite da parte di insider. Firmando l’avviso, il dichiarante conferma di non essere a conoscenza di informazioni materiali non divulgate riguardanti le operazioni di NIKE.

NIKE, Inc. (NKE) ha presentado un Formulario 144 indicando que un insider tiene la intención de vender 1.644 acciones Clase B, valoradas en aproximadamente 123.152 $, a través de Fidelity Brokerage a partir del 05 de agosto de 2025. Las acciones fueron adquiridas apenas cuatro días antes (01 de agosto de 2025) mediante vesting de acciones restringidas y representan solo el 0,00014% de las 1.188 mil millones de acciones en circulación de la empresa. No se reportaron otras ventas de insiders en los últimos tres meses. Al firmar el aviso, el declarante afirma no tener conocimiento de información material no divulgada sobre las operaciones de NIKE.

NIKE, Inc. (NKE)는 내부자가 2025년 8월 5일 이후 Fidelity Brokerage를 통해 약 123,152달러 상당의 1,644 클래스 B 주식을 매도할 의사를 밝힌 Form 144를 제출했습니다. 해당 주식은 제한 주식 권리 행사를 통해 단 4일 전인 2025년 8월 1일에 취득되었으며, 회사의 총 발행 주식 11억 8,800만 주0.00014%에 해당합니다. 지난 3개월간 다른 내부자 매도는 보고되지 않았습니다. 신고서에 서명함으로써 신고자는 NIKE의 운영과 관련된 미공개 중요 정보가 없음을 확인했습니다.

NIKE, Inc. (NKE) a déposé un Formulaire 144 indiquant qu’un initié prévoit de vendre 1 644 actions de classe B, d’une valeur d’environ 123 152 $, via Fidelity Brokerage à compter du 5 août 2025. Ces actions ont été acquises seulement quatre jours plus tôt (1er août 2025) par le biais d’un vesting d’actions restreintes et représentent seulement 0,00014 % des 1,188 milliard d’actions en circulation de la société. Aucune autre vente d’initiés n’a été signalée au cours des trois derniers mois. En signant cet avis, le déclarant affirme ne pas avoir connaissance d’informations matérielles non divulguées concernant les opérations de NIKE.

NIKE, Inc. (NKE) hat ein Formular 144 eingereicht, das darauf hinweist, dass ein Insider beabsichtigt, 1.644 Class-B-Aktien im Wert von etwa 123.152 $ über Fidelity Brokerage am oder nach dem 05. August 2025 zu verkaufen. Die Aktien wurden erst vier Tage zuvor (01. August 2025) durch restricted-stock vesting erworben und stellen lediglich 0,00014 % der insgesamt 1,188 Milliarden ausstehenden Aktien des Unternehmens dar. In den letzten drei Monaten wurden keine weiteren Insiderverkäufe gemeldet. Mit der Unterzeichnung der Mitteilung bestätigt der Einreicher, dass ihm keine nicht offengelegten wesentlichen Informationen über die Geschäftstätigkeiten von NIKE bekannt sind.


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the
Securities Exchange Act of 1934
 
August 05, 2025
 
Commission File Number 001-14978
 
SMITH & NEPHEW plc
(Registrant’s name)
 
Building 5, Croxley Park, Hatters Lane
Watford, England, WD18 8YE
 (Address of principal executive office)
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F a         Form 40-F __
 
 

5 August 2025
 
Share Buyback Programme
 
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, announces that it intends to undertake a share buyback programme to return $500 million to shareholders, while maintaining leverage, and without compromising growth plans.
 
This additional return of value will be undertaken in the second half of 2025 and reflects strong cash generation and balance sheet resulting from the 12-Point Plan transformation. Further details are contained in Smith+Nephew's Second Quarter and First Half 2025 Results announcement published today, 5 August 2025.
 
To implement the buyback programme, Smith+Nephew has entered into a non-discretionary agreement with J.P. Morgan Securities plc in relation to the latter's purchase, acting as riskless principal, of the Company's ordinary shares of USD $0.20 each for an aggregate price of up to USD $500 million as part of the programme.
 
Shares acquired by J.P. Morgan Securities will be subsequently repurchased by Smith+Nephew, held as treasury shares and then either be cancelled or retained for the purpose of satisfying awards under employee share plans. The Programme will commence on 5 August 2025 and will end no later than 31 December 2025. The purpose of the Programme is to reduce Smith+Nephew's issued share capital by returning surplus capital to shareholders.
 
Any purchase of shares contemplated by this announcement will be carried out on Recognised Investment Exchanges[1] and will be effected with certain pre-set parameters. The maximum number of ordinary shares which may be purchased by the Company is 87,440,566 ordinary shares, which is the maximum pursuant to the authority granted by shareholders at the Company's 2025 Annual General Meeting.
 
The programme will be executed in accordance with (and subject to the existence of and/or the limits prescribed by) the general authority granted by shareholders at the Company's relevant Annual General Meeting; and will be conducted within the parameters prescribed by the Market Abuse Regulation 596/2014/EU as it forms part of domestic law by virtue of section 3 of the European Union (Withdrawal) Act 2018 (as amended) and Chapter 9 of the Financial Conduct Authority's UK Listing Rules. No repurchases will be made in respect of the Company's American Depositary Receipts.
 
J.P. Morgan Securities plc may undertake transactions in Shares (which may include sales and hedging activities, in addition to purchases which may take place on any available trading venue or on an over the counter basis) during the period of the Programme in order to manage its market exposure under the Programme. Disclosure of such transactions will not be made by J.P. Morgan Securities plc as a result of or as part of the Programme, but J.P. Morgan Securities plc will continue to make any disclosures it is otherwise legally required to make.
 
Smith+Nephew will make further announcements in due course following any repurchase of shares. There is no guarantee that the programme will be implemented in full or that any shares will be bought back by the Company.
 
Enquiries:
 
Investors
 
Cora McCallum
+44 (0) 1923 477433
Smith+Nephew
 

Media
 
Charles Reynolds
+44 (0) 1923 477314
Smith+Nephew
 
 
LEI: 213800ZTMDN8S67S1H61
 
About Smith+Nephew
 
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 17,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
 
Founded in Hull, UK, in 1856, we now operate in around 100 countries and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
 
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on XLinkedInInstagram or Facebook.
 
Forward-looking Statements
 
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC's website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.
 
◊ Trademark of Smith+Nephew. Certain marks are registered with the US Patent and Trademark Office.
 
 
[1] Note: Includes the London Stock Exchange, CBOE Europe Limited and Turquoise and Aquis Stock Exchange.
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
 
 
 
Smith & Nephew plc
 
 
(Registrant)
 
 
 
 
 
 
Date: August 05, 2025
By:
/s/ Helen Barraclough
 
 
Helen Barraclough
 
 
Company Secretary

FAQ

How many NIKE shares are being sold under this Form 144?

The filing covers 1,644 Class B shares.

What is the estimated market value of the planned NIKE share sale?

The aggregate market value is reported at $123,152.04.

When is the anticipated sale date for the NIKE shares?

The filer lists an approximate sale date of 05 Aug 2025.

How were the shares acquired by the insider?

The insider received the shares on 01 Aug 2025 through restricted-stock vesting as compensation.

Which broker will execute the NIKE share sale?

The shares are to be sold via Fidelity Brokerage Services LLC.
Smith & Nephew

NYSE:SNN

SNN Rankings

SNN Latest News

SNN Latest SEC Filings

SNN Stock Data

15.52B
437.85M
0.03%
7.55%
0.62%
Medical Devices
Healthcare
Link
United Kingdom
Watford